Use of a VEGF antagonist to treat angiogenic eye disorders

  • US 9,254,338 B2
  • Filed: 07/12/2013
  • Issued: 02/09/2016
  • Est. Priority Date: 01/13/2011
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating an angiogenic eye disorder in a patient, said method comprising sequentially administering to the patient a single initial dose of a VEGF antagonist, followed by one or more secondary doses of the VEGF antagonist, followed by one or more tertiary doses of the VEGF antagonist;

  • wherein each secondary dose is administered 2 to 4 weeks after the immediately preceding dose; and

    wherein each tertiary dose is administered at least 8 weeks after the immediately preceding dose;

    wherein the VEGF antagonist is a VEGF receptor-based chimeric molecule comprising (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO;

    2;

    (2) a VEGFR2 component comprising amino acids 130-231 of SEQ ID NO;

    2; and

    (3) a multimerization component comprising amino acids 232-457of SEQ ID NO;

    2.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×